Guidelines for the Use of Antiretroviral Agents in Pediatric HIV Infection

The information in the brief version is excerpted directly from the full-text guidelines. The brief version is a compilation of the tables and boxed recommendations.

  •   Table of Contents

Download Guidelines

Entry and Fusion Inhibitors

Maraviroc

Last Updated: April 14, 2020; Last Reviewed: April 14, 2020

Maraviroc (MVC, Selzentry)
Maraviroc (MVC, Selzentry)
Formulations
Oral Solution: 20 mg/mL
Tablets: 25 mg, 75 mg, 150 mg, 300 mg
Dosing Recommendations Selected Adverse Events
Neonate and Infant Dose:
  • Maraviroc (MVC) is not approved by the Food and Drug Administration (FDA) for use in neonates or infants.
Pediatric Dose:
  • MVC is approved by the FDA for use in ART-experienced children aged ≥2 years and weighing ≥10 kg who have CCR5-tropic HIV-1.
Recommended Maraviroc Dose for Treatment-Experienced Children Aged ≥2 Years and Weighing ≥10 kg: Tablets or Oral Solution
Weight Band Twice-Daily Dosing Oral Solution 20 mg/mL Tablets
Recommended doses when MVC is given with potent cytochrome P450 (CYP) 3A inhibitors (with or without a potent CYP3A inducer), including all protease inhibitors (PIs) except tipranavir/ritonavir (TPV/r)
10 kg to <20 kg 50 mg 2.5 mL Two 25-mg tablets
20 kg to <30 kg 75 mg to 80 mg 4 mL One 75-mg tablet
30 kg to <40 kg 100 mg 5 mL One 25-mg tablet and one 75-mg tablet
≥40 kg 150 mg 7.5 mL One 150-mg tablet
Recommended doses when MVC is given with non-interacting drugs, such as nucleoside reverse transcriptase inhibitors (NRTIs), nevirapine (NVP), enfuvirtide (T-20), TPV/r, and raltegravir (RAL)
10 kg to <20 kg Not recommended. Data are insufficient to make dosing recommendations for children weighing <30 kg and receiving non-interacting medications.
20 kg to <30 kg Not recommended. Data are insufficient to make dosing recommendations for children weighing <30 kg and receiving non-interacting medications.
30 kg to <40 kg 300 mg 15 mL One 300-mg tablet
≥40 kg 300 mg 15 mL One 300-mg tablet
Recommended doses when MVC is given with potent CYP3A inducers (without a potent CYP3A inhibitor), including efavirenz (EFV) and etravirine (ETR)
Children in all weight bands Not recommended. Data are insufficient to make dosing recommendations.

Recommended Maraviroc Dose for Adults: Tablets
When Coadministered With Dose
Potent CYP3A inhibitors (with or without a potent CYP3A inducer), including all PIs except TPV/r 150 mg twice daily
Non-interacting concomitant medications, including NRTIs, T-20, TPV/r, NVP, and RAL 300 mg twice daily
Potent CYP3A inducers (without a potent CYP3A inhibitor), including EFV and ETR 600 mg twice daily
  • Nausea, vomiting
  • Abdominal pain, diarrhea
  • Cough
  • Upper respiratory tract infections
  • Fever
  • Rash
  • Hepatotoxicity (which may be preceded by severe rash and/or other signs of systemic allergic reaction)
  • Postural hypotension (generally seen in patients with severe renal insufficiency)
  • Dizziness
Special Instructions
  • MVC is recommended for use in patients who only have CCR5-tropic HIV-1. Before using MVC, conduct testing with an HIV tropism assay (see Drug-Resistance Testing in the Adult and Adolescent Antiretroviral Guidelines) to exclude the presence of CXCR4-tropic or mixed/dual-tropic HIV. Do not use MVC if CXCR4-tropic or mixed/dual-tropic HIV is present.
  • MVC can be given without regard to food.
  • Instruct patients on how to recognize symptoms of allergic reactions or hepatitis.
  • Use caution when administering MVC to patients with underlying cardiac disease.
Metabolism/Elimination
  • MVC is a substrate of CYP3A4. If a patient is receiving antiretroviral agents or other medications that act as CYP3A inducers or inhibitors, the dose of MVC should be adjusted accordingly.
Maraviroc Dosing in Patients with Hepatic Impairment:
  • Use caution when administering MVC to patients with hepatic impairment; MVC concentrations may be increased in these patients.
Maraviroc Dosing in Patients with Renal Impairment:
  • There are no data to recommend specific doses of MVC for pediatric patients with mild or moderate renal impairment. MVC is contraindicated for pediatric patients with severe renal impairment or end-stage renal disease who are on regular hemodialysis and who are receiving potent CYP3A inhibitors.
  • Refer to the manufacturer’s prescribing information for the appropriate doses to use in adult patients with renal impairment.

Download Guidelines